Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 14;17(9):2116.
doi: 10.3390/s17092116.

Ultra-Sensitive NT-proBNP Quantification for Early Detection of Risk Factors Leading to Heart Failure

Keum-Soo Song  1 , Satish Balasaheb Nimse  2 , Mukesh Digambar Sonawane  3 , Shrikant Dashrath Warkad  4 , Taisun Kim  5
Affiliations

Ultra-Sensitive NT-proBNP Quantification for Early Detection of Risk Factors Leading to Heart Failure

Keum-Soo Song et al. Sensors (Basel). .

Abstract

Cardiovascular diseases such as acute myocardial infarction and heart failure accounted for the death of 17.5 million people (31% of all global deaths) in 2015. Monitoring the level of circulating N-terminal proBNP (NT-proBNP) is crucial for the detection of people at risk of heart failure. In this article, we describe a novel ultra-sensitive NT-proBNP test (us-NT-proBNP) that allows the quantification of circulating NT-proBNP in 30 min at 25 °C in the linear detection range of 7.0-600 pg/mL. It is a first report on the application of a fluorescence bead labeled detection antibody, DNA-guided detection method, and glass fiber membrane platform for the quantification of NT-proBNP in clinical samples. Limit of blank, limit of detection, and limit of quantification were 2.0 pg/mL, 3.7 pg/mL, and 7 pg/mL, respectively. The coefficient of variation was found to be less than 10% in the entire detection range of 7-600 pg/mL. The test demonstrated specificity for NT-proBNP without interferences from bilirubin, intra-lipid, biotin, and hemoglobin. The serial dilution test for plasma samples containing various NT-proBNP levels showed the linear decrement in concentration with the regression coefficient of 0.980-0.998. These results indicate that us-NT-proBNP test does not suffer from the interference of the plasma components for the measurement of NT-proBNP in clinical samples.

Keywords: 9G DNAChip; DAGON; NT-proBNP; cardiovascular disease; heart failure; left ventricular hypertrophy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1
Scheme 1
A simple and fast detection of NT-proBNP level in the clinical samples by DAGON method on the glass fibre membrane platform.
Figure 1
Figure 1
(A) Standard curve, (B–D) depict the linearity of the test in clinical samples containing 162 pg/mL, 183.3 pg/mL, and 551.9 pg/mL of NT-proBNP after spiking, respectively.
Figure 2
Figure 2
(A) Inter-assay precision profiles for the us-NT-proBNP test; (B) Passing and Bablok regression analyses of results for 58 clinical samples (range: 26.3–163.3 pg/mL) by us-NT-proBNP test and NT-proBNP assay.
Figure 3
Figure 3
Determination of interference of (A) Bilirubin (0.2 mg/mL), (B) Intra-lipid (0.2%) emulsion (Plasma samples containing 200 pg/mL and 420 pg/mL of NT-proBNP arranged from top to bottom, respectively).
Figure 4
Figure 4
Determination of interference of (A) haemoglobin (1 mg/mL); (B) biotin (30 ng/mL) in clinical samples containing 60 pg/mL (top) and 400 pg/mL (bottom) of NT-proBNP.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Health Organization Cardiovascular Diseases (CVDs), Factsheet. [(accessed on 9 June 2017)]; Available online: http://www.who.int/mediacentre/factsheets/fs317/en/
    1. Roth G.A., Forouzanfar M.H., Moran A.E., Barber R., Nguyen G., Feigin V.L., Naghavi M., Mensah G.A., Murray C.J. Demographic and epidemiologic drivers of global cardiovascular mortality. N. Engl. J. Med. 2015;372:1333–1341. doi: 10.1056/NEJMoa1406656. - DOI - PMC - PubMed
    1. World Health Organization . Global Status Report on Noncommunicable Diseases. World Health Organization; Geneva, Switzerland: 2011. [(accessed on 9 June 2017)]. Available online: http://www.who.int/nmh/publications/ncd_report_full_en.pdf.
    1. Mozaffarian D., Benjamin E.J., Go A.S., Arnett D.K., Blaha M.J., Cushman M., De Ferranti S., Després J.P., Fullerton H.J., Howard V.J., et al. Heart disease and stroke statistics—2015 update: A Report from the American Heart Association. Circulation. 2015;131:e29–e322. doi: 10.1161/CIR.0000000000000152. - DOI - PubMed
    1. Mozaffarian D., Benjamin E.J., Go A S., Arnett D.K., Blaha M.J., Cushman M., Das S.R., De Ferranti S., Després J.P., Fullerton H.J., et al. Heart disease and stroke statistics—2016 update: A Report from the American Heart Association. Circulation. 2016;133:e38–e360. doi: 10.1161/CIR.0000000000000350. - DOI - PubMed
-